Others News

Launch of Contract Testing Services for Skin Sensitization Tests Using Animal Testing Alternatives

J-TEC Acquires Rights to a Patent for Human Intestinal Epithelial Models Using iPS Cell-Derived Organoids from Takara Bio

Sysmex and J TEC Sign a Research Collaboration Agreement

Regarding Sterility Testing in Regenerative Medicine and Cell Therapy

Japan Tissue Engineering and VCCT Inc. Form a Capital and Business Alliance to Put iPS Cell-Based Regenerative Medical Products to Practical Use

J-TEC and Shiven Biotech Sign a Distributor Agreement Concerning the Sale of Cultured Human Tissue for Research Use

Sysmex and J-TEC Sign a Basic Agreement to Advance Manufacturing Capabilities for Regenerative Medicine and Cell Therapy

Announcement of NHI Listing of Autologous Cultured Epidermis Maintaining Melanocytes “JACEMIN” for the Treatment of Vitiligo

Announcement on the Progress of the Clinical Trial of Allogeneic Cultured Epidermis Allo-JaCE03

The In Vitro Skin Sensitization Test Method EpiSensA Using the Human 3-Dimensional Cultured Tissue Model LabCyte EPI-MODEL24 Becomes an International Standard

Submission of a Request of Approval for Partial Changes to Autologous Cultured Cartilage JACC Aimed at an Expansion of Indication to Include Knee Osteoarthritis

Autologous Cultured Cartilage JACC: Progress in Clinical Trial aimed at Expanding Indication for Knee Osteoarthritis

Regenerative Medicine for the Knee using Autologous Cultured Cartilage: Application all over Japan – a track record of usage in all 47 prefectures

Teijin, J-TEC and Resilience Form Business Alliance to Spur Development of New Regenerative Medicine Technologies

Notice of press release from Nagoya University

Nagoya University and Chulalongkorn University, Collaboration in Thailand Successful treatment of malignant lymphoma using non-viral vector-based CAR-T cells

Notice of Marketing Approval for Autologous Cultured Epidermis “JACEMIN” for the Treatment of Vitiligo

Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform

Production Department Senior Manager wins “8th Annual Achievement Award for the Development of Female Technologists”

Supporting the Early Commercialization of Regenerative Medicine for Corneal Endothelium

— Partial Product Development Contract with ActualEyes Inc. —

Toward creation of a database for results of skin irritation tests using an alternative to animal testing

– With a grant from JSAAE, 6 corporations continue contributing jointly to the cosmetics industry –

Re-examination of Autologous Cultured Cartilage “JACC”

J-TEC announces application for marketing approval for stable vitiligo treatment: Autologous Cultured Epidermis "ACE02"

J-TEC announces application for marketing approval for stable vitiligo treatment: Autologous Cultured Epidermis "ACE02"

The research group from Jikei University School of Medicine and St. Marianna University School of Medicine launched an investigator-initiated clinical trial of autologous nasal mucosal epithelial cell sheets for middle ear cholesteatoma

— J-TEC commissioned with contract manufacture of the IP —

10th Technology and Management/Innovation Award “METI Minister's Award” Winner

“Popularization of Japan’s First Regenerative Medical Product – Autologous Cultured Epidermis JACE”

Announcement of Start of Clinical Trial for Allogeneic Cultured Epidermis “Allo-JaCE03”

- J-TEC’s first allogeneic cell therapy product: Submitted notification of clinical trial plan to realize ready-made product that can be swiftly provided to patients -

Announcing approval of Autologous Cultured Oral Mucosal Epithelium “Ocural” for NHI listing

Listing effective December 1 creates new option for treatment of bilateral limbal stem cell deficiency

Announcement : Acceptance of Development Project in FY2021 AMED Program for the Promotion of Innovation through Industrial-Academic Collaboration

Marketing approval obtained for Autologous Cultured Oral Mucosal Epithelium “Ocural”

— World’s first regenerative medical product using oral mucosal epithelial cells for the treatment of limbal stem cell deficiency —

Reviewed and acknowledged by MHLW subcommittee: approval of autologous cultured oral mucosal epithelial cell sheet (development code: COMET01)

Change in Parent Company from Fujifilm Corporation to Teijin Limited.

Towards the Creation of Novel Regenerative Medical Products in the Field of Ophthalmology Marketing Approval Application for Autologous Cultured Oral Mucosal Epithelium (Development Name: COMET01)

Providing new treatment options with Japan’s first regenerative medical product in ophthalmology field Obtained marketing approval for autologous cultured corneal epithelium "Nepic"

Announcement of Application for Manufacturing and Marketing Approval for Cultured Autologous Corneal Epithelium (Development name: EYE-01M)

- First application for a regenerative medical product in the field of ophthalmology in Japan -

Expansion of Indication for Autologous Cultured Epidermis “JACE”: Dystrophic and Junctional Epidermolysis Bullosa

Toward Expansion of Indication to Include Secondary Knee Osteoarthritis from Trauma, Etc. Submission of CTN for Clinical Trial of Autologous Cultured Cartilage “JACC”

Eye Irritancy Testing Method using “LabCyte CORNEA-MODEL24” Human 3-Dimensional Cultured Corneal Epithelium Included in OECD Test Guideline

Submission of CTN for Clinical Trial of Autologous Cultured Epidermis with Melanocyte, “ACE02” for the Treatment of Leukoderma

Japan Tissue Engineering, Nagoya University, and Shinshu University sign patent license agreement for the development of a low-cost manufacturing technology for autologous CAR-T cell therapy with enhanced targeting efficiency against CD 19-positive acute lymphoblastic leukemia

Japan Tissue Engineering provides support to rescue victims of Taiwan water park explosion Autologous cultured epidermis JACE® treatment for severe burn victims

Notice Regarding Change in President and CEO

Notice Concerning Change in Parent Company

Notification Regarding the Exercise of Subscription Rights Through Private Allocation to a Third Party

Notice Concerning Issue of Subscription Rights Through Private Allocation

J-TEC Received Government Approval to Manufacture and Sell Autologous Cultured Cartilage JACC in Japan

Released FY2010 Financial Report.

Announcement: Opening of Singapore Representative Office

Announcement: Establishment of a Representative Office in Singapore

Announcement Rearding Issuance of New Shares by Third Party Allocation, and a Change in the Largest Shareholder

Released FY2009 Financial Report.

Announcement: J-TEC has submitted an application for manufacturing and sales of autologous cultured cartilage

Released FY2008 Financial Report.

On January 1 2009, J-TEC's autologous cultured epidermis "JACE" was listed as an item covered by the National Health Insurance in Japan.

J-TEC has received reimbursement approval for the autologous cultured epidermis "JACE" in Japan. The reimbursement will start in Janurary 2009.

Released FY2007 Financial Report.

J-TEC joined the Jasdaq Securities Exchange's Neo market for venture firms on December 21, 2007.

On October 29, 2007, J-TEC officially received government approval to culture and sell autologous cultured epidermis JACE for serious burns treatment in Japan.

J-TEC got the go-ahead by the health ministry panel of the Ministry of Health, Labor and Welfare, for the manufacturing & sales approval of cultured epidermis in Japan.

Awarded the highest prize in the New Business Awards 2006, sponsored by the Chubu Economic Federation.

J-TEC awarded the Japan Bioventure Grand Prize, the top honor in the 4th Japan Bioventure Grand Prize awards.

Started marketing of LabCyte

Awarded President of the Science Council of Japan's Award at the 16th Awards for Excellence in Collaboration Between Industry, Academia, and Government.

Obtained authorization to begin clinical trials of autologous cultured cartilage.

Started multicenter clinical trials of autologous cultured epidermis.

Japan Tissue Engineering Co., Ltd established.